We are contributing to the complete synthesis of a small-molecule screening collection whose members have properties that facilitate discovery, optimization, and manufacturing of biologically active small molecules.([@ref1]) Recognizing the value of including complex pyridines([@ref2]) in this resource, we conceived of a previously unexplored transition-metal-mediated \[2 + 2 + 2\]-cycloaddition of silyl ether-tethered diynes with nitriles as a route to bicyclic pyridines. The tether was used to control regioselectivity and to enable modification of the products into complex monocyclic pyridines. Here, we report an irradiation-free Co(I)-catalyzed \[2 + 2 + 2\]-cycloaddition reaction yielding complex, bicyclic pyridines. Assaying the resulting compounds in a cell-based screen that reveals a visual phenotype of a targeted signaling pathway resulted in the discovery of an inhibitor of neuregulin-1/ErbB4-mediated neuronal differentiation.

The discovery of well-defined metal complexes (Co, Rh, Ir, Ru, Ti, and Ni) as catalysts that induce cycloaddition has advanced the synthesis of pyridines considerably.([@ref3]) The CpCo(CO)~2~ catalyzed reaction has been widely used in recent years.([@ref4]) These reactions typically require high temperature *and* irradiation to generate active Co(I) by liberating CO, limiting overall generality. Alternatives (CpCo(cod)([@ref5]) and CpCo(ethylene)~2~([@ref6])) exist that liberate active catalyst under milder conditions, but these precatalysts are difficult to handle.([@ref7]) While studies have explored the effect of altering the ligand sphere around cobalt,([@ref8]) the effect of exogenous ligands and solvents on catalyst performance has not been studied extensively.([@ref9])

When **1**([@ref10]) was treated with 2-methoxy-5-pyridinecarbonitrile and stoichiometric CpCo(CO)~2~**2** in xylenes (140 °C, 200 W irradiation), a moderate conversion to **5** was achieved (Table [1](#tbl1){ref-type="table"}, entry 1), while the regioisomeric pyridine **6** was not detected. The regiochemistry of the pyridines was determined by NoE; data are provided in the [Supporting Information](#si1){ref-type="notes"}.([@ref11]) We were unable to drive the reaction to completion by increasing nitrile stoichiometry (1.5−5.0 equiv). When 25 mol % of **2** was used, only 17% conversion was observed. Due to the hindered nature of these substrates,([@ref12]) we postulated that catalyst decomposition may be competitive. Accordingly, we attempted to stabilize CpCo(I). Surprisingly, a dramatic solvent effect was noted, despite the reports of nonpolar, noncoordinating solvents as being optimal in these reactions. 1,2-Dimethoxyethane (entry 3), 1,2-dichloroethane (entry 4), 2-methyltetrahydrofuran (entry 9), and THF (entry 10) all resulted in *catalytic* reactions using 25 mol % of **2**. Attempts to stabilize CpCo(I) further by introducing chelating ligands resulted in lower conversions relative to the control reaction in THF, suggesting a possible trade-off between ligand stabilization and substrate coordination (entries 11−15).([@ref13]) Gratifyingly, when the reaction was performed in THF *in the absence of irradiation*, conversion increased to \>95%. Attempts to reduce the temperature abolished catalytic activity, which is expected due to the stability of the CO ligands. NiCl~2~(dppp)/Zn,([@ref14]) CoCl~2~/Zn,([@ref15]) and RhCl(PPh~3~)~3~,([@ref16]) resulted in recovery of starting materials or complex mixtures of products.

###### Development of a Catalytic \[2 + 2 + 2\] Cycloaddition
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Experimental procedures provided in the [Supporting Information](#si1){ref-type="notes"}. Nitrile: 2-methoxy-5-pyridine carbonitrile.

Solvents were degassed by bubbling argon for 20 min prior to use. 1,2-DME: dimethoxyethane. 1,2-DCE: dichloroethane. 1,2-DCB: dichlorobenzene. TCE: trichloroethylene. DMA: dimethylacetamide.

1,4-Dioxane, pyridine, and DMA gave \<2% conversion.

Additives at 50 mol %.

Conversions determined by ^1^H NMR spectroscopy.

Reaction ran without irradiation.

Based on the above data, we adopted a standard procedure using degassed THF at 140 °C in a sealed tube without irradiation. Using these conditions, nitriles **7**−**18** were screened to determine the generality of the reaction (Table [2](#tbl2){ref-type="table"}). The electronics of the nitrile did not have a predictable effect on either conversion or yield. Aromatic (entry 10), heteroaromatic (entries 1 and 9), benzylic (entry 3), as well as primary (entry 8) and secondary (entry 12) aliphatic nitriles were effective reactants. Pyrazine-containing nitrile **15**, nitriles bearing free hydroxyl and amine groups (**16** and **17**), and strongly deactivated nitriles (e.g., **18**) failed to give detectable amounts of pyridines. In selected cases where conversions were low or where products coeluted chromatographically with diyne **1**, the desired heterocycles were obtained with \>95% conversion by increasing loading of **2** (entries 5 and 6). Attempts to react 2π-systems other than nitriles (e.g., alkynes, isocyanates, and thioisocyanates) failed.([@ref17])

###### Effect of the Nitrile Component
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Nitriles: **9**: acrylonitrile. **10**: 5-methylfuran-2-carbonitrile. **14**: cyclopropylnitrile.

Method A: crude reaction mixtures were filtered through a 4 g silica plug to remove insoluble cobalt species; combined fractions were assayed for conversion by ^1^H NMR. Organics were then chromatographed to obtain yields.

Conversions determined by ^1^H NMR spectroscopy.

∗ = coelution with diyne using standard chromatographic conditions. Regioselectivity was determined on the basis of 1D NOE studies of **21** ([Supporting Information](#si1){ref-type="notes"}).

The silylated diynes used in this study possess several sites that can be modified to provide pyridines with different appendages and fused rings of various sizes (Table [3](#tbl3){ref-type="table"} and Figure [1](#fig1){ref-type="fig"}).([@ref18]) Even large substituents on the silylated acetylene were accommodated (R^1^ = *i*-Pr, entry 5; R^1^ = *o*-tol, entry 7). Likewise, the distal alkyne need not be terminal (entries 3 and 4 (R^2^ = Me) and 9 (R^2^ = Et), allowing fully substituted pyridines to be accessed. In the case of **37**, a mixture of regioisomers (**43**−**44**) was observed in a 2.7:1 ratio; this is the only case in which the alternative mode of addition was observed. Separation of the alkyne moieties by the addition of an extra methylene in the tether provided a fused silabicyclic compound **47** in 50% yield (entry 9). A modified protocol was devised that dispenses with the intermediate filtration step (methods A vs B, Table [3](#tbl3){ref-type="table"}), often resulting in elevated yields. The diisopropylsilyl moiety could be easily extruded (Figure [1](#fig1){ref-type="fig"}, five examples).

###### Scope and Limitations with Respect to the Diyne
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Method A is described in Table [2](#tbl2){ref-type="table"}. Method B: Organics were directly chromatographed to obtain yields for **42−46**.

Conversions determined by ^1^H NMR (method A). Since method B involves immediate chromatography, conversion was not determined for these reactions.

![Modification of cycloaddition products.](ol-2008-004936_0008){#fig1}

![(a) PC12 cells. (b) PC12 cells treated with neuregulin. (c) PC12 cells transfected with ErbB4. (d) PC12 + ErbB4 cells treated with neuregulin showing neurite outgrowth. (e) PC12 + ErbB4 cells treated with neuregulin in the presence of the silylated precursor to **52**. (f) PC12 + ErbB4 cells treated with neuregulin in the presence of **52**. Pyridine **52** was found to be a potent inhibitor of this cellular activity (EC~50~ = 0.30 µM). See the [Supporting Information](#si1){ref-type="notes"} for details.](ol-2008-004936_0007){#fig2}

Pyridine-containing small molecules (e.g., Gleevec([@ref19]) and 2-methyl-6-(phenylethynyl)pyridine (MPEP)([@ref20])) are known that have a wide range of biological activities. Twenty-five bicyclic and monocyclic pyridines were included in a small-molecule screening collection that was assayed using a live-cell, image-based, high-content screen. PC12 cells were engineered to express the ErbB4 receptor tyrosine kinase in order to monitor ErbB4-dependent cell differentiation upon activation by neuregulin-1 (Nrg1), a secreted activator of ErbB4.([@ref21]) ErbB4 (Figure [2](#fig2){ref-type="fig"}) belongs to the family of receptor tyrosine kinases, which are membrane receptors that regulate cell proliferation, invasion, and differentation in response to extracellular protein factors. ErbB4 is the least studied of the epidermal growth factor receptor (EGFR) subfamily, yet both gene expression and genetic analyses suggest that ErbB4 is involved in the progression of breast cancer and in the pathogenesis of brain disorders such as schizophrenia.^[@ref22],[@ref23]^ Discovering specific small-molecule modulators of ErbB4 receptor signaling could facilitate both an understanding of the functions of ErbB4 and the development of novel therapeutics. In the ErbB4-expressing PC12 cells, but not in the wild-type PC12 cells lacking ErbB4, neuregulin induces neurite outgrowth. Using this assay, pyridine **52** was discovered to be a potent inhibitor of the neuregulin/ErbB4 pathway, with an approximate EC~50~ of 0.30 µM (Figure [2](#fig2){ref-type="fig"}F), while its bicyclic precursor (Figure [2](#fig2){ref-type="fig"}E) is inactive at 20 µM, the highest concentration tested.

In summary, we report an irradiation-free cycloaddition protocol with broad generality for the synthesis of pyridines from silylated diynes and nitriles using THF to induce catalyst turnover.([@ref24]) The silyl ether proved useful for both enabling an expanded set of complex pyridines and illuminating structure/activity relationships, as highlighted by the discovery of compound **52** as a potent inhibitor of the neuregulin/ErbB4-dependent signaling pathway. Studies to expand the use of this reaction in the build/couple/pair strategy of diversity synthesis and to elucidate compound **52**ʼs cellular mechanism of pathway modulation are underway.
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